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bjectives We conducted the “TAXUS Woman” analysis to assess the inﬂuence of sex on long-term
utcomes after percutaneous coronary intervention using paclitaxel-eluting stents (PES) in a broad
pectrum of patients.
ackground Previous studies indicate that the sex gap suggesting worse outcomes in women has
arrowed. However, limited data are available on long-term sex-based outcomes with drug-eluting
tents despite their extensive use in current practice.
ethods We analyzed 2,271 PES-treated patients (women  665), from 5 randomized trials and 7,492
ES-treated patients (women  2,449) from 2 “real-world” registries. The trial and registry datasets were
tratiﬁed by sex to compare long-term outcomes. Additionally, the outcomes in PES-treated women were
ompared with bare-metal stent–treated women (n  395) in the randomized trials.
esults In the randomized trials, PES-treated women had a lower target lesion revascularization
TLR) rate (11.5% vs. 22.6%, p  0.001) than bare-metal stent–treated women, with no signiﬁcant
ex-based differences in death, myocardial infarction, stent thrombosis, or TLR through 5 years. In
oth the trials and the registries, although women had more adverse baseline characteristics includ-
ng advanced age, hypertension, and diabetes, they had similar outcomes to men. In expanded-use
atients, however, women showed signiﬁcantly higher rates of death and TLR, although only the
igher TLR rate was conﬁrmed by multivariate analysis.
onclusions This study of nearly 10,000 patients including more than 3,000 women demonstrates that
espite their higher-risk proﬁle, women have comparable beneﬁts to men from percutaneous coronary
ntervention with PES except for a slightly higher revascularization rate in the high-risk cohort. (J Am
oll Cardiol Intv 2010;3:1250–9) © 2010 by the American College of Cardiology Foundation
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1251oronary artery disease is the leading cause of death for
oth men and women in the U.S. and other developed
ountries. For more than 2 decades, more women than
en have died of this disease (1). However, women
ontinue to be under-represented in prospective clinical
rials evaluating coronary revascularization strategies.
urthermore, compared with men, women tend to have
ore comorbid conditions at baseline and potentially
omplex coronary anatomy, challenging the validity of
aking treatment decisions for women based on data
erived from predominantly male populations. A better
nderstanding of sex-specific outcomes would potentially
llow individualized revascularization strategies to be
eveloped for the large and growing population of
omen with coronary artery disease.
See page 1260
Previous sex-based studies in patients undergoing percu-
aneous coronary intervention (PCI) and coronary artery
ypass graft have reported higher in-hospital mortality and
ncreased risk for adverse outcomes in women than in men
2–4). A recent report indicates that, compared with men,
omen continue to be at an increased risk of operative
ortality after isolated coronary artery bypass graft, al-
hough subsequent studies in patients undergoing PCI with
are-metal stents (BMS) indicate that the sex gap in
utcomes has narrowed (5–7). In patients undergoing PCI,
he sex gap has narrowed further with the introduction of
rug-eluting stents (DES), where the angiographic and
linical benefits were found to be independent of sex in
andomized trial cohorts with simple de novo lesions (8,9).
owever, the influence of sex on long-term DES outcomes
as not been fully elucidated, and it is not clear if the pattern
f equality holds true outside the realm of low-risk patient
opulations. Therefore, we compared sex-based outcomes
n patients receiving paclitaxel-eluting stents (PES) in both
he randomized trials and the “real-world” registries.
ethods
tudy description. Data from the TAXUS pivotal trials and
he ATLAS trial were pooled. The TAXUS I, II SR, IV,
nd V trials (10–13) were prospective, multicenter, random-
zed, double-blind, controlled trials where increasingly com-
lex patients with a single de novo lesion in a native
oronary artery were randomized to receive either a
onoraria from Boston Scientific and Cordis/Johnson & Johnson. Dr. Ormiston has
eceived research grants and support from Boston Scientific, Johnson & Johnson,
bbott Vascular, and Elixir Medical as well as honoraria from Boston Scientific and
bbott Vascular and is an advisory board member for Boston Scientific, Abbott
ascular, and Devax. Dr. Stone has received research grants from Boston Scientificnd Abbott Vascular. Dr. Turco has received research support and consulting fees
M
aaclitaxel-eluting Taxus slow-release (commercialized)
tent or an otherwise identical BMS (Boston Scientific
orporation, Natick, Massachusetts). The TAXUS III trial
valuating the feasibility and safety of PES for the treatment
f in-stent restenosis and the TAXUS VI trial using the
nvestigational moderate-release PES were not included in
his analysis (14,15). Follow-up was available through 5
ears for the TAXUS I, II, IV, and V trials. The ATLAS
rial (16) is a prospective single-arm trial of the next
eneration Taxus Liberté stent (Boston Scientific Corpora-
ion) with follow-up available through 4 years.
Data from the ARRIVE (TAXUS Peri-Approved
egistry: A Multicenter Safety Surveillance) 1 and 2
egistries (17) were pooled and analyzed separately from
he trial data. The ARRIVE registries are 2-phase
ost-market registries undertaken to study Taxus Ex-
ress2 stent system usage in routine clinical practice
hrough 2 years.
The pooled analysis design for the randomized trials and
egistries is illustrated in Figure 1.
nd points and deﬁnitions. The
ollowing end points were ex-
mined to assess the influence
f sex on long-term safety and
ffectiveness of PES: death,
yocardial infarction (MI),
tent thrombosis, and target le-
ion revascularization (TLR).
eath was defined as all-cause
ortality. Myocardial infarc-
ion was defined as either the
evelopment of pathological Q
aves lasting at least 0.04 s in
t least 2 contiguous leads with
n elevated creatine kinase-
yocardial band fraction level or, in the absence of Q
aves, an elevation of creatine phosphokinase levels to
reater than twice the upper limit of normal with an
levated creatine kinase-myocardial band level. Stent
hrombosis data, adjudicated by the Academic Research
onsortium “definite or probable” definition, were used
n the present analysis (18). Target lesion revasculariza-
ion was defined as repeat revascularization by either PCI
r coronary artery bypass graft for ischemia with angio-
raphic restenosis of at least 50% of the luminal diameter
nywhere within the stent or the 5-mm borders proximal
r distal to the stent. Data from the original databases as
rom and is a Speakers’ Bureau member for Abbott, Boston Scientific, and Medtronic.
r. Joshi is a full-time employee of Boston Scientific. Dr. Baim was a full-time
mployee and a stockholder of Boston Scientific. Drs. Gerber and Colombo have
eported that they have no relationships to disclose. Dr. Baim is deceased.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RVD  reference vessel
diameter
TLR  target lesion
revascularizationanuscript received April 30, 2010; revised ma
ccepted August 6, 2010.nuscript received July 16, 2010,
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1252djudicated by an independent clinical events committee
or each individual study were used in the present
nalysis.
tatistical methods. All statistical analyses were performed by
iostatisticians at Boston Scientific Corporation. Potential bias
as minimized by performing the analysis according to the
ntent-to-treat principle by including all patients randomized
n the pooled trials and all patients receiving the Taxus stent in
he pooled registries.
For continuous variables, comparison between the
roups was performed with Student t test. Categorical
ariables were compared by the chi-square test. Time-to-
vent data were calculated and displayed as Kaplan-Meier
stimates with comparison between groups by the log-
ank test. Statistical significance was set at p  0.05.
nnualized s were calculated for every year after the
ndex procedure using the person-year method. The
pproximate Poisson method (19) was used to calculate
he 95% confidence intervals (CIs). Hazard rate differ-
nces between groups were calculated using the log-rank
est.
Predictors of clinical outcomes were assessed with
tepwise Cox proportional hazards regression with sig-
ificance set at 0.05, with the exception of sex, which was
orced into the model. Variables included in the model
or the randomized trials were age, congestive heart
ailure, diabetes requiring medication, previous coronary
rtery bypass graft, percentage diameter stenosis, in-stent
Figure 1. TAXUS Woman Analysis Design
Patients from 5 randomized trials and 2 “real-world” registries were pooled sepcute gain, hyperlipidemia, calcification, reference vessel siameter (RVD), previous MI, minimum lumen diame-
er, unstable angina, left anterior descending artery versus
on–left anterior descending location, lesion location,
ypertension, smoking, treatment group (Taxus Express
s. Taxus Liberté), total occlusion, sex, and lesion length.
or the registries, the variables included age, congestive
eart failure, diabetes requiring medication, left main
tenting, prior MI, diabetes requiring insulin, cardiogenic
hock, graft stenting, hypertension, lesion length 28
m, sex, hyperlipidemia, multiple planned stents, in-
tent restenosis, lesion length, total occlusion, left ante-
ior descending location, RVD, smoking, bifurcation,
ultiple lesions treated, RVD 2.5 mm, percentage
iameter stenosis, and baseline acute MI.
esults
andomized trials. A total of 2,797 patients were enrolled
n the TAXUS trials; 1,400 were randomized to PES and
,397 to BMS. The 1,400 PES-treated patients were
ooled with 871 PES-treated patients from the ATLAS
rial (Fig. 1). Of the 2,271 pooled patients, 665 (29.3%)
ere women and 1,606 were men.
ASELINE CHARACTERISTICS. As shown in Table 1, women
ere significantly older than men, with lower body weight,
ore unstable angina, congestive heart failure, medically
reated diabetes, hypertension, prior history of coronary artery
isease, and peripheral vascular disease. They also had slightly
ly to compare sex-based outcomes.maller RVD than men did (2.63 0.46 mm vs. 2.79 0.52
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1253m, p 0.001). In contrast, men were more likely to have had
previous MI, PCI, and coronary artery bypass graft.
AFETY AND EFFICACY END POINTS. In the randomized
rials, PES-treated women had significantly lower TLR
ate than BMS-treated women did, with no significant
ifferences in the rates of death, MI, and stent throm-
osis between PES and BMS through 5-year follow-up
Fig. 2). Comparison of PES-treated women with PES-
reated men (Table 2) showed no significant sex differ-
nces in all-cause death, MI, and TLR either at 1-year or
etween 1 and 5 years. However, women appeared to
Table 1. Baseline Clinical and Lesion Characteristics
Variable W
Age, yrs
Weight, lbs 1
Cardiac history
Stable angina
Unstable angina
Silent ischemia
Congestive heart failure
Previous myocardial infarction
Previous percutaneous coronary intervention
Previous coronary artery bypass graft
Cardiac risk factors
Current smoking
Diabetes, medically treated
Hypertension
Hyperlipidemia
History of coronary artery disease
Comorbid conditions
Peripheral vascular disease
Previous transient ischemic attack
Previous cerebrovascular accident
Renal disease
Lesion characteristics (by QCA)
Reference vessel diameter, mm
Minimum lumen diameter, mm
Diameter stenosis, % 6
Lesion length, mm 1
Left anterior descending vessel location
Bend 45°
Tortuosity
Modiﬁed ACC/AHA lesion type
A
B1
B2
C
B2/C
Values are mean  SD (n) or % (count/sample size). The p values for
variables were calculated by the chi-square test.
ACC  American College of Cardiology; AHA  American Heart A
angiography.uffer less definite/probable stent thrombosis in 0 to 1 pear than men did (0.31% vs. 1.27%, p  0.04), although this
nding was not sustained during the subsequent years.
The Kaplan-Meier curves in Figure 3 demonstrate the
ack of differences between genders in death, MI, stent
hrombosis, and TLR rates over 5 years. At hospital
ischarge, 100% of women and 99.9% of men were receiv-
ng dual antiplatelet therapy (p  0.52). The antiplatelet
ompliance remained similar through follow-up, having
allen to 36.1% for women and 37.4% for men at 5 years.
ULTIVARIATE PREDICTORS OF 5-YEAR CLINICAL OUTCOMES.
djusted for other covariates, sex was not a significant
atients Receiving PES in the Randomized Trials
(n  665) Men (n  1,606) p Value
11.1 (665) 61.4 10.7 (1,606) 0.001
37.1 (397) 200.8 38.4 (970) 0.001
(365/663) 57.8% (929/1,606) 0.22
(248/663) 31.5% (496/1,577) 0.006
(67/665) 12.5% (201/1,602) 0.10
(51/664) 3.9% (63/1,605) 0.001
(171/663) 31.8% (501/1,577) 0.005
(174/622) 33.8% (500/1,481) 0.01
(39/663) 9.3% (146/1,577) 0.008
(138/665) 23.5% (378/1,606) 0.15
(223/665) 21.9% (352/1,606) 0.001
(519/665) 69.5% (1,116/1,606) 0.001
(477/665) 72.8% (1,166/1,602) 0.61
(372/600) 52.6% (762/1,450) 0.001
(63/615) 7.6% (112/1,475) 0.046
(7/187) 2.9% (14/475) 0.60
(27/453) 3.8% (41/1,080) 0.06
(23/453) 3.9% (42/1,080) 0.29
0.46 (659) 2.79 0.52 (1,597) 0.001
0.35 (658) 0.89 0.35 (1,569) 0.24
11.54 (658) 67.98 11.14 (1,569) 0.09
7.31 (659) 14.72 7.31 (1,592) 0.84
(259/664) 41.2% (661/1,603) 0.33
(148/622) 22.2% (328/1,476) 0.43
(74/622) 10.5% (155/1,475) 0.35
(50/622) 7.1% (105/1,478) 0.45
(140/622) 24.4% (361/1,478) 0.35
(259/622) 38.6% (571/1,478) 0.20
(173/622) 29.8% (441/1,478) 0.35
(432/622) 68.5% (1,012/1,478) 0.66
uous variables were calculated by Student t test and for categorical
ion; PES  paclitaxel-eluting stent(s); QCA  quantitative coronaryfor P
omen
64.9
71.3
55.1%
37.4%
10.1%
7.7%
25.8%
28.0%
5.9%
20.8%
33.5%
78.0%
71.7%
62.0%
10.2%
3.7%
6.0%
5.1%
2.63
0.87
7.09
4.65
39.0%
23.8%
11.9%
8.0%
22.5%
41.6%
27.8%
69.5%
contin
ssociatredictor of any of the adverse outcomes; death (hazard
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1254atio [HR]: 0.83, 95% CI: 0.60 to 1.14), MI (HR: 1.12,
5% CI: 0.80 to 1.58), stent thrombosis (HR: 0.56, 95% CI:
.27 to 1.16), and TLR (HR: 0.96, 95% CI: 0.72 to 1.26).
egistries. A total of 2,487 and 5,005 patients were
nrolled in the ARRIVE 1 and ARRIVE 2 registries,
Figure 2. Clinical Outcomes for Women in Randomized Trials
Kaplan-Meier estimates of 5-year cumulative rates of death (A), myocardial infa
bosis (C), and target lesion revascularization (D) for women receiving paclitaxe
1.5 SE. ARC  Academic Research Consortium; BMS  bare-metal stent(s); P
Table 2. Annualized Hazard Rates for Patients Receiving PES in the
Randomized Trials
Women
(n  665)
Men
(n  1,606) p Value
All-cause death
0–1 yr 1.69% 1.71% 0.97
1–5 yrs 2.20% 1.96% 0.48
0–5 yrs 2.08% 1.90% 0.54
Myocardial infarction
0–1 yr 4.47% 4.06% 0.69
1–5 yrs 1.00% 0.87% 0.62
0–5 yrs 1.86% 1.60% 0.42
ARC stent thrombosis (deﬁnite/probable)
0–1 yr 0.31% 1.27% 0.04
1–5 yrs 0.33% 0.35% 0.88
0–5 yrs 0.33% 0.57% 0.13
Target lesion revascularization
0–1 yr 7.75% 6.69% 0.39
1–5 yrs 1.60% 1.58% 0.95
0–5 yrs 2.85% 2.67% 0.67iARC Academic Research Consortium; PES paclitaxel-eluting stent(s).espectively. Of these 7,492 pooled PES-treated patients,
,794 (64%) were classified as expanded-use based on
atient and/or lesion characteristics considered outside
he 2,698 simple-use population. The expanded-use co-
ort included patients with acute MI, lesion length 28
m, RVD 2.5 mm, multivessel stenting, bifurcation
esions, in-stent restenosis, vein graft, renal disease, and
hronic total occlusion. Of the 2,698 simple-use patients,
21 (34%) were women and of the 4,794 expanded-use
atients, 1,528 (32%) were women.
ASELINE CHARACTERISTICS. The registry data demon-
trated a similar pattern of increased adverse baseline
haracteristics for women compared with men (Table 3).
omen were older, more likely to be hypertensive, have
iabetes, previous stroke, and smaller RVD. Men, by
ontrast, were more likely to have had a previous MI,
CI, and coronary artery bypass graft. They were also
ore likely to have left main and multivessel disease.
AFETY AND EFFICACY END POINTS. Simple-use registry pa-
ients showed no significant sex differences in death, MI, stent
hrombosis, and TLR through 2 years (Table 4). Also, as in the
andomized trial patients, women tended to have lower stent
hrombosis rates (albeit not statistically significant) than men.
The Kaplan-Meier curves in Figure 4 demonstrate the
bsence of sex-based differences in the simple-use patients.
n the expanded-use patients, however, women had signif-
(B), Academic Research Consortium–deﬁned deﬁnite/probable stent throm-
ng stent(s) versus bare-metal stent(s) in the randomized trials. Error bars are
aclitaxel-eluting stent(s).rction
l-eluticantly higher death and TLR rates than men (Fig. 5).
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1255ultivariate predictors of 2-year clinical outcomes. The
igher rates of death and TLR in women in the
xpanded-use patients could be confounded by the higher
aseline risk factors in women than in men. This is
upported by multivariate analysis, wherein sex was not
ound to be a significant independent predictor of any
dverse outcomes among simple-use patients; death (HR:
.90, 95% CI: 0.60 to 1.34), MI (HR: 0.94, 95% CI: 0.54
o 1.64), stent thrombosis (HR: 0.62, 95% CI: 0.29 to
.34), and TLR (HR: 1.39, 95% CI: 0.98 to 1.98). In the
xpanded-use patients, sex was not a significant predictor
f death (HR: 1.05, 95% CI: 0.85 to 1.31), MI (HR:
.18, 95% CI: 0.85 to 1.63), and stent thrombosis (HR:
.13, 95% CI: 0.80 to 1.61) but remained a significant
redictor of TLR (HR: 1.36, 95% CI: 1.11 to 1.67).
Further, subgroup analysis in the expanded-use
atients indicated that the increase in the TLR rate
n women was generalized across high-risk subgroups,
lthough no individual subgroup reached statistical sig-
ificance. The subgroup hazard ratios for TLR (women
s. men) were as follows: acute MI (HR: 1.48, 95% CI:
.86 to 2.57), in-stent restenosis (HR: 1.00, 95% CI:
.59 to 1.72), lesion length 28 mm (HR: 0.94, 95%
I: 0.61 to 1.44), RVD 2.5 mm (HR: 1.26, 95% CI:
.56 to 2.86), multivessel stenting (HR: 1.20, 95% CI:
.85 to 1.69), bifurcation lesion (HR: 1.09, 95% CI: 0.66
o 1.79), chronic total occlusion (HR: 1.38, 95% CI: 0.53
Figure 3. Sex-Based Clinical Outcomes in the Randomized Trials
Kaplan-Meier estimates of 5-year cumulative rates of death (A), myocardial in
stent thrombosis (C), and target lesion revascularization (D) for women ver
als. Error bars are 1.5 SE.o 3.59). wiscussion
ue to the relative under-representation of women in
CI trials, and the prior suggestions that women have
orse outcomes than men, more detailed investigations
f the influence of sex on PCI outcomes in current
ractice are needed. To our knowledge, the “TAXUS
oman” analysis, which included more than 3,000
omen, is the largest evaluation to date that examines the
nfluence of sex on long-term performance of a single
ES across low- to high-risk patient/lesion characteris-
ics. This analysis demonstrated that women had signif-
cantly more adverse baseline risk factors, yet had com-
arable safety and efficacy outcomes to men.
The data on 665 women in the randomized trials showed
hat PES provided a significant reduction in TLR compared
ith BMS through 5 years without an associated increase in
ther adverse events. The study extends upon the previous
tudies (20,21). It is important to note that because of the
linded nature of these studies, the use of dual antiplatelet
herapy over time was the same in both the PES and BMS
rms.
In the randomized trials and in the simple-use registry
atients, there were no significant sex-based differences in
ong-term safety or efficacy outcomes. In the expanded-use
egistry patients, however, univariate analysis showed that
omen had significantly higher 1- and 2-year death rates,
n (B), Academic Research Consortium (ARC)–deﬁned deﬁnite/probable
en for patients receiving paclitaxel-eluting stent(s) in the randomized tri-farctio
sus mhich was also observed as a trend in a recent study (21).
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1256ultivariate analysis, however, showed that this observed
ncrease in mortality in women in the expanded-use patients
as attributable to their higher baseline comorbidities (includ-
ng age and diabetes), making sex per se a marker of a more
evere clinical profile rather than a variable that directly affects
he outcome. This observation is in alignment with previous
tudies that reported no differences in short- or long-term
ifferences in mortality between men and women after adjust-
ent for baseline covariates in the modern era of PCI with
ES in patients with de novo lesions (22,23).
A more interesting finding of this study is the increase in
LR for women in the expanded-use registry population. Our
nding is supported by a previous report wherein female sex
as been reported as an independent predictor of restenosis
ollowing sirolimus-eluting stent implantation in high-risk
atients (24). Also a recent pooled sex-based analysis compar-
ng the everolimus-eluting stent and PES demonstrated that
rrespective of the stent type, a higher 2-year TLR rate was
bserved in women than in men (7.3 vs. 4.2, p  0.03) (25).
ex differences in intravascular ultrasound measures of neoin-
Table 3. Baseline Clinical and Lesion Characteristics for Patients Receivin
Simple-Us
Variable Women (n  921) Men (n
Age, yrs 65.9 11.5 (921) 61.5 1
Cardiac history
Congestive heart failure 6.0% (55/921) 4.4% (7
Previous myocardial infarction 23.6% (217/921) 28.6% (5
Previous percutaneous coronary
intervention
34.1% (310/910) 35.2% (6
Previous coronary artery bypass graft 9.5% (87/919) 12.4% (2
Cardiac risk factors
Current smoking 21.3% (196/921) 25.7% (4
Diabetes, medically treated 28.9% (266/921) 25.0% (4
Hypertension 80.0% (737/921) 73.0% (1
Hypercholesteromia 72.5% (668/921) 75.4% (1
Comorbid conditions
Previous stroke 5.9% (54/921) 4.6% (8
Renal disease 0.0% (0/921) 0.0% (0
Multivessel disease 25.0% (230/921) 28.3% (5
Left main disease 0.0% (0/921) 0.0% (0
Lesion characteristics
Reference vessel diameter (mm) 2.92 0.36 (920) 2.97 0
Left anterior descending vessel location 43.2% (398/921) 38.9% (6
Modiﬁed ACC/AHA lesion type
A 27.1% (250/921) 23.0% (4
B1 45.8% (422/921) 47.2% (8
B2 24.8% (228/921) 26.2% (4
C 7.7% (71/921) 8.9% (1
B2/C 32.0% (295/921) 34.5% (6
Values are mean SD (n) or % (count/sample size). The p values for continuous variables were calc
Undef undefined; other abbreviations as in Table 1.imal hyperplasia have been reported previously (26). The fact that increases in the rate of repeat revascularization were
imited to the expanded-use registry population in the PES
egistries suggests that this slightly greater level of neointimal
yperplasia may only become clinically relevant in more com-
lex lesions. Unlike the increase in death rate, the increase in
LR for women persisted after multivariate adjustment, sug-
esting a fundamental biologic difference or perhaps the effect
f other unmeasured confounders.
Some concerns have been raised about the potential for
ncreased very late (after 1 year) rates of stent thrombosis with
ES versus BMS (27). It has been postulated that DES might
e more vulnerable to this complication due to potential
uppression of neointimal hyperplasia and the altered vascular
esponses by the antiproliferative effects responsible for the
esired reduction in restenosis. Although this event occurs
ith low frequency, it is associated with significant morbidity
nd mortality. In that context, it is of interest that a moderately
ignificant reduction in stent thrombosis at 12 months in favor
f women was observed in both the trial and simple-use
egistry patients. However, this initial benefit in terms of stent
in the Registries
Expanded-Use
77) p Value Women (n  1,528) Men (n  3,266) p Value
77) 0.001 67.7 11.8 (1,528) 63.7 11.6 (3,266) 0.001
) 0.08 8.8% (135/1,528) 7.4% (242/3,266) 0.09
7) 0.005 37.7% (576/1,528) 43.5% (1,421/3,266) 0.001
9) 0.54 34.1% (513/1,504) 39.6% (1,282/3,235) 0.001
2) 0.023 18.2% (277/1,520) 28.2% (918/3,260) 0.001
7) 0.012 20.2% (309/1,528) 24.6% (803/3,266) 0.001
7) 0.029 33.3% (509/1,528) 27.3% (893/3,266) 0.001
777) 0.001 82.2% (1,256/1,528) 73.5% (2,401/3,266) 0.001
777) 0.11 77.0% (1,176/1,528) 76.4% (2,494/3,266) 0.65
) 0.14 9.4% (143/1,528) 5.8% (189/3,266) 0.001
Undef 4.4% (67/1,528) 3.8% (124/3,266) 0.33
7) 0.07 38.0% (581/1,528) 44.4% (1,451/3,266) 0.001
Undef 6.3% (97/1,528) 8.0% (262/3,266) 0.04
77) 0.001 2.87 0.45 (1,528) 2.97 0.48 (3,266) 0.001
7) 0.030 47.1% (720/1,528) 40.5% (1,323/3,266) 0.001
7) 0.018 14.4% (220/1,528) 13.5% (441/3,266) 0.40
7) 0.49 38.5% (588/1,528) 38.2% (1,246/3,266) 0.83
7) 0.41 41.1% (628/1,528) 41.5% (1,357/3,266) 0.77
7) 0.30 27.8% (425/1,528) 28.9% (945/3,266) 0.42
7) 0.20 64.7% (988/1,528) 66.2% (2,161/3,266) 0.31
y Student t test and for categorical variables were calculated by the chi-square test.g PES
e
 1,7
1.2 (1,7
9/1,777
08/1,77
20/1,75
20/1,77
56/1,77
44/1,77
,297/1,
,339/1,
1/1,777
/1,777)
03/1,77
/1,777)
.37 (1,7
91/1,77
09/1,77
39/1,77
66/1,77
58/1,77
13/1,77
ulated bhrombosis was not sustained to 5 years, nor did it persist after
m
a
d
c
t
b
d
m
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1257ultivariate adjustment for other baseline differences. It was
lso not explicable by women being more likely to adhere to
ual antiplatelet therapy, given similar rates of medication
ompliance over time, for men and women. It is possible
Table 4. Annualized s for Patients Receiving PES in t
Sim
Women
(n  921) (n
All-cause death
0–1 yr 2.47%
1–2 yrs 2.19%
0–2 yrs 2.34%
Myocardial infarction
0–1 yr 1.25%
1–2 yrs 0.98%
0–2 yrs 1.12%
ARC stent thrombosis (deﬁnite/probable)
0–1 yr 0.68%
1–2 yrs 0.37%
0–2 yrs 0.53%
Target lesion revascularization
0–1 yr 4.13%
1–2 yrs 2.84%
0–2 yrs 3.27%
Abbreviations as in Tables 1, 2, and 3.
Figure 4. Sex-Based Clinical Outcomes in the Registries (Simple-Use)
Kaplan-Meier estimates of 2-year cumulative rates of death (A), myocardial inf
thrombosis (C), and target lesion revascularization (D) for women versus men
bars are 1.5 SE.hat the lower body weight of women compared with the
ody weight of men could lead to higher dosing of clopi-
ogrel (milligrams per kilograms body weight), and thus
ore effective antiplatelet effect during the first year, but
gistries
se Expanded-Use
77) p Value
Women
(n  1,528)
Men
(n  3,266) p Value
0.68 5.37% 3.82% 0.02
0.65 4.21% 3.64% 0.39
0.55 4.82% 3.74% 0.02
0.65 2.95% 2.51% 0.41
0.72 1.23% 1.53% 0.46
0.96 2.15% 1.99% 0.64
0.34 2.51% 2.21% 0.54
0.39 1.00% 1.31% 0.41
0.29 1.77% 1.74% 0.93
0.20 8.06% 5.69% 0.004
0.59 4.15% 3.86% 0.67
0.19 5.82% 4.60% 0.02
(B), Academic Research Consortium (ARC)–deﬁned deﬁnite/probable stent
ple-use patients receiving paclitaxel-eluting stent(s) in the registries. Errorhe Re
ple-U
Men
 1,7
2.22%
1.92%
2.07%
1.47%
0.83%
1.14%
1.06%
0.64%
0.80%
3.14%
2.46%
2.60%arction
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1258ecent data suggest that sex is a significant predictor of
eightened platelet reactivity despite dual antiplatelet ther-
py in patients undergoing PCI (28). Hence, we cannot
xclude that this observation of reduced first-year stent
hrombosis in women was the result of a type 2 error,
aking further clarification from a larger prospective study
arranted before concluding that there is a real difference in
arly stent thrombosis for women.
tudy limitations. This study based on a large cohort of
ES-treated women was subjected to careful ascertainment
f follow-up events. However, as a post hoc subset analysis
f prospective trials and registries it still must be considered
s an observational and hypothesis-generating study. In
ddition, although the results of this analysis cannot be
pplied directly to women with more diffuse disease, acute
I, or those requiring multivessel intervention, the inclu-
ion of expanded-use conditions in the real-world registries
ay provide insight into sex differences when DES are used
n such high-risk patients. Finally, it remains to be deter-
ined whether DES other than Taxus would show the
ame relative results in women compared with men.
onclusions
hese data indicate that the overall beneficial effects of
ES in reducing revascularization compared with BMS
Figure 5. Sex-Based Clinical Outcomes in the Registries (Expanded-Use)
Kaplan-Meier estimates of 2-year cumulative rates of death (A), myocardial infa
thrombosis (C), and target lesion revascularization (D) for women versus men
bars are 1.5 SE.re generalizable to women. There were no sex-basedifferences in key adverse outcomes such as death, MI,
LR, or stent thrombosis in the randomized trial and
imple-use registry patients. However, a slightly higher
ate of TLR was observed in women in the overall
xpanded-use registry patients, across the subgroups
sually associated with an increased risk of restenosis.
onetheless, this large sex-based analysis demonstrates
hat PCI with PES is a safe and effective treatment
ption for women with coronary artery disease suitable
or revascularization with DES.
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